Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients

Leuk Res. 2013 Jul;37(7):784-9. doi: 10.1016/j.leukres.2013.02.010. Epub 2013 Mar 22.

Abstract

The aim of this study was to evaluate effect of c-KIT mutations on RUNX1/RUNX1T1 fusion transcript expression in patients with t(8;21)-positive AML. Fifty patients diagnosed with t(8;21)-positive AML for recent 10 years were enrolled. Patients with c-KIT mutations tended to achieve a greater than 3-log reduction in RUNX1/RUNX1T1 fusion transcript expression less frequently than patients without mutations from 6 to 12 months of follow-up. They have difficulties to obtain molecular complete remission and experience molecular relapse more frequently and rapidly than those without mutations. These results support poor prognostic impact of c-KIT mutations in t(8;21)-positive AML.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Chromosomes, Human, Pair 21 / genetics*
  • Chromosomes, Human, Pair 8 / genetics*
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • DNA, Neoplasm / genetics
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Neoplasm Recurrence, Local / genetics*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / therapy
  • Oncogene Proteins, Fusion / genetics*
  • Prognosis
  • Proto-Oncogene Proteins c-kit / genetics*
  • RUNX1 Translocation Partner 1 Protein
  • Real-Time Polymerase Chain Reaction
  • Retrospective Studies
  • Survival Rate
  • Translocation, Genetic / genetics*
  • Young Adult

Substances

  • AML1-ETO fusion protein, human
  • Core Binding Factor Alpha 2 Subunit
  • DNA, Neoplasm
  • Oncogene Proteins, Fusion
  • RUNX1 Translocation Partner 1 Protein
  • Proto-Oncogene Proteins c-kit